PRTA at a glance
PROTHENA CORP PUBLIC LTD CO (PRTA, SEC CIK 1559053) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PROTHENA CORP PUBLIC LTD CO (PRTA) reported revenue of $9.7 million (down 92.8% from FY2024) and a net loss of $244.1 million. Diluted EPS was -$4.53.
- The most recent insider open-market purchase reported on Form 4 was by SCULLY WILLIAM P on October 2, 2026 of 100,000 shares at $8.57 per share.
- In the last 90 days, PRTA insiders reported 8 open-market purchases ($5.0M) and 2 open-market sales ($136K) on Form 4, a net purchase of $4.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.7M
- −92.8% vs prior year
- Insiders · 90 days
- 8 buys · 2 sells
- Net +$4.9M
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- 2026 operating and investing cash use outlook: approximately $18 million–$23 million
- Contractual obligations $9.446 million, including operating leases $7.484 million
- Brisbane sublease obligations $14.9 million, with approximately $7.4 million outstanding
- No off-balance-sheet arrangements as of June 30, 2026
Risk Factors
- No material changes stated from 2025 Form 10-K; risks remain substantially carried forward
- Accumulated deficit $1.3 billion despite six-month net income of $14.1 million
- Additional capital required; cash and equivalents $288.2 million expected to fund operations for at least twelve months
- Privacy compliance exposure under GDPR, with penalties up to €20 million or 4% of global annual turnover
- Clinical development risk from Phase 3 prasinezumab, Phase 3 coramitug, Phase 2 moponetug, and Phase 1 PRX019 trials
AI summary of the PRTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial details
Item EX-99.1: Item EX-99.1
- Q2 net loss $18.6M versus $125.8M loss; six-month net income $14.1M driven by $50.0M Novo Nordisk milestone
- Cash, equivalents and restricted cash $289.1M with no debt; year-end guidance reduced to approximately $259M midpoint
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shane M. Cooke and Dennis J. Selkoe re-elected as directors through 2029
- KPMG LLP appointment ratified for fiscal 2026; Audit Committee authorized to approve auditor remuneration
AI summaries of PRTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PRTA
Don't miss the next PRTA filing
- Alerts as it files. A push when PRTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PRTA, by share count.
- Ask anything. An AI agent that reads every PRTA filing and answers with sources.
PRTA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SCULLY WILLIAM P | Buy | Oct 2, 2026 | 100,000 | $8.57 |
| SCULLY WILLIAM P | Buy | Sep 29, 2026 | 162,000 | $8.68 |
| SCULLY WILLIAM P | Buy | Sep 28, 2026 | 103,500 | $8.60 |
| SCULLY WILLIAM P | Buy | Sep 18, 2026 | 100,000 | $8.43 |
| SCULLY WILLIAM P | Buy | Sep 2, 2026 | 27,000 | $9.47 |
| SCULLY WILLIAM P | Buy | Aug 20, 2026 | 50,000 | $8.79 |
| SCULLY WILLIAM P | G | Aug 18, 2026 | 627,553 | - |
| SCULLY WILLIAM P | G | Aug 17, 2026 | 336,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $91.4M | $135.2M | $9.7M |
| Operating Income | -$191.0M | -$154.6M | -$214.6M |
| Net Income | - | -$122.3M | -$244.1M |
| Op. Margin | -209.1% | -114.4% | -2216.4% |
| Net Margin | - | -90.5% | -2520.6% |
| Balance Sheet | |||
| Total Assets | $696.4M | $547.1M | $326.8M |
| Equity | $561.4M | $486.9M | $280.5M |
| ROE | - | -25.1% | -87.0% |
| Per Share | |||
| EPS | $-2.76 | $-2.27 | $-4.53 |
| Cash Flow | |||
| Operating CF | -$133.9M | -$150.1M | -$163.6M |
Source: XBRL data in PROTHENA CORP PUBLIC LTD CO (PRTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
PRTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Oct 2, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PRTA SEC filings: frequently asked questions
Are PRTA insiders buying or selling?
In the last 90 days, PROTHENA CORP PUBLIC LTD CO (PRTA) officers, directors and 10% owners reported 8 open-market purchases worth $5.0 million by 1 insider and 2 open-market sales worth $135,975 by 2 insiders on Form 4, a net purchase of $4.9 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was PRTA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PROTHENA CORP PUBLIC LTD CO (PRTA) reported revenue of $9.7 million (down 92.8% from FY2024) and a net loss of $244.1 million. Diluted EPS was -$4.53. The figures come from the XBRL data in the 10-K.
What did PRTA report in its latest 8-K?
PROTHENA CORP PUBLIC LTD CO (PRTA) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest PRTA SEC filings?
PROTHENA CORP PUBLIC LTD CO (PRTA) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on October 6, 2026.
What is PRTA's SEC CIK number?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s SEC Central Index Key (CIK) is 1559053. EDGAR lists every PRTA filing under that number.
Ask anything about PRTA
The research agent reads PRTA's filings, financials, insider trades and 13F holders, then answers with sources.